Apeloa Pharmaceutical Co.,Ltd (SHE:000739)
15.46
+0.42 (2.79%)
Apr 1, 2025, 2:45 PM CST
SHE:000739 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
Operating Revenue | 11,957 | 11,440 | 10,506 | 8,910 | 7,852 | Upgrade
|
Other Revenue | 65.35 | 33.92 | 39.1 | 32.44 | 28.09 | Upgrade
|
Revenue | 12,022 | 11,474 | 10,545 | 8,943 | 7,880 | Upgrade
|
Revenue Growth (YoY) | 4.77% | 8.81% | 17.92% | 13.49% | 9.28% | Upgrade
|
Cost of Revenue | 9,225 | 8,621 | 8,075 | 6,579 | 5,700 | Upgrade
|
Gross Profit | 2,796 | 2,853 | 2,470 | 2,364 | 2,179 | Upgrade
|
Selling, General & Admin | 1,121 | 1,125 | 985.33 | 906.43 | 957.56 | Upgrade
|
Research & Development | 641.47 | 624.87 | 532.92 | 446.22 | 350.06 | Upgrade
|
Other Operating Expenses | 12.76 | 23.3 | 31.76 | 33.05 | 38.83 | Upgrade
|
Operating Expenses | 1,785 | 1,775 | 1,563 | 1,405 | 1,356 | Upgrade
|
Operating Income | 1,012 | 1,078 | 906.8 | 959.39 | 823.59 | Upgrade
|
Interest Expense | -32.2 | -43.77 | -59.23 | -35.72 | -16.01 | Upgrade
|
Interest & Investment Income | 92.17 | 113.47 | 75.83 | 165.7 | 86.9 | Upgrade
|
Currency Exchange Gain (Loss) | 58.38 | 38.13 | 93.42 | -23.09 | -73.61 | Upgrade
|
Other Non Operating Income (Expenses) | 2.21 | -8.35 | -5.38 | -3.58 | -2.33 | Upgrade
|
EBT Excluding Unusual Items | 1,132 | 1,177 | 1,011 | 1,063 | 818.54 | Upgrade
|
Gain (Loss) on Sale of Investments | -10.13 | -21.7 | -82.61 | -23.62 | 47.45 | Upgrade
|
Gain (Loss) on Sale of Assets | 0.28 | 1.33 | 1.37 | 0.28 | 8.52 | Upgrade
|
Asset Writedown | -8.4 | -15.2 | -4.67 | -7.95 | -10.2 | Upgrade
|
Other Unusual Items | 89.22 | 62.93 | 86.52 | 82.67 | 96.85 | Upgrade
|
Pretax Income | 1,203 | 1,205 | 1,012 | 1,114 | 961.15 | Upgrade
|
Income Tax Expense | 172.44 | 149.34 | 22.89 | 158.53 | 144.42 | Upgrade
|
Earnings From Continuing Operations | 1,031 | 1,055 | 989.17 | 955.55 | 816.73 | Upgrade
|
Minority Interest in Earnings | 0.27 | 0.03 | 0 | - | - | Upgrade
|
Net Income | 1,031 | 1,055 | 989.17 | 955.55 | 816.73 | Upgrade
|
Net Income to Common | 1,031 | 1,055 | 989.17 | 955.55 | 816.73 | Upgrade
|
Net Income Growth | -2.30% | 6.69% | 3.52% | 17.00% | 47.58% | Upgrade
|
Shares Outstanding (Basic) | 1,163 | 1,169 | 1,174 | 1,179 | 1,179 | Upgrade
|
Shares Outstanding (Diluted) | 1,163 | 1,169 | 1,174 | 1,179 | 1,179 | Upgrade
|
Shares Change (YoY) | -0.52% | -0.40% | -0.38% | -0.00% | 0.01% | Upgrade
|
EPS (Basic) | 0.89 | 0.90 | 0.84 | 0.81 | 0.69 | Upgrade
|
EPS (Diluted) | 0.89 | 0.90 | 0.84 | 0.81 | 0.69 | Upgrade
|
EPS Growth | -1.78% | 7.12% | 3.91% | 17.00% | 47.57% | Upgrade
|
Free Cash Flow | 748.01 | 400.9 | 817 | -90.18 | 742.41 | Upgrade
|
Free Cash Flow Per Share | 0.64 | 0.34 | 0.70 | -0.08 | 0.63 | Upgrade
|
Dividend Per Share | 0.356 | 0.317 | 0.297 | 0.285 | 0.243 | Upgrade
|
Dividend Growth | 12.34% | 6.70% | 4.21% | 17.28% | 47.27% | Upgrade
|
Gross Margin | 23.26% | 24.86% | 23.42% | 26.43% | 27.66% | Upgrade
|
Operating Margin | 8.42% | 9.39% | 8.60% | 10.73% | 10.45% | Upgrade
|
Profit Margin | 8.58% | 9.20% | 9.38% | 10.69% | 10.37% | Upgrade
|
Free Cash Flow Margin | 6.22% | 3.49% | 7.75% | -1.01% | 9.42% | Upgrade
|
EBITDA | 1,576 | 1,631 | 1,296 | 1,318 | 1,168 | Upgrade
|
EBITDA Margin | 13.11% | 14.21% | 12.29% | 14.74% | 14.82% | Upgrade
|
D&A For EBITDA | 563.97 | 553.06 | 389.43 | 358.64 | 344.06 | Upgrade
|
EBIT | 1,012 | 1,078 | 906.8 | 959.39 | 823.59 | Upgrade
|
EBIT Margin | 8.42% | 9.39% | 8.60% | 10.73% | 10.45% | Upgrade
|
Effective Tax Rate | 14.33% | 12.40% | 2.26% | 14.23% | 15.03% | Upgrade
|
Revenue as Reported | 12,022 | 11,474 | 10,545 | 8,943 | 7,880 | Upgrade
|
Advertising Expenses | 11.29 | 9.67 | 1.61 | 1.86 | 2.96 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.